Summary
Erythromycin kinetics were studied in 17 patients with end stage renal failure treated with maintenance haemodialysis and 9 normal volunteers to discover if dialysis patients needed a modified dose. The elimination half life in dialysis patients (on dialysis days) was similar to that reported in normal subjects. Only small amounts of drug appeared in the dialysate, no patient loosing more than 9 mg in one dialysis. Both patients and volunteers had similar plasma concentrations 8 h after the end of a 5-day course. Protein-binding did not change significantly during dialysis and was similar to that reported in normal subjects. We conclude that dialysis patients requiring 1.5 g of erythromycin stearate daily or less can be given normal doses.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Austin KL, Mather LE, Philpot CR, McDonald PJ (1980) Intersubject and dose-related variability after intravenous administration of erythromycin. Br J Clin Pharmacol 10: 273–280
Davidman M, Goodman Y, Macleod LE (1966) Antibiotic disappearance in renal failure and haemodialysis. Can Med Assoc J 94: 662
Gordon RC, Regamey C, Kirby NMM (1973) Serum protein binding of erythromycin, lincomycin and clindamycin. J Pharm Sci 62: 1074–1077
Henry J, Turner P, Garland M, Esmieu F (1980) Plasma and salivary concentrations of erythromycin after administration of three different formulations. Postgrad Med J 55: 707–710
Huin G, Tillement JP, Lhoste F, Rapin M, Soussy GJ, Dural J (1980) Erythromycin Pharmacokinetics in man. J Int Med Res 8: (Suppl 2) 9
Iliopoulou A, Thin RN, Turner P (1981) Fluorimetric and microbiological assays for erythromycin in plasma and vaginal washings. Br J Vener Dis 57: 263–267
Kanfer A, Daniel F, Vigeral P, Mery JP (1980) Oto-toxicité de l'erythromycine au cours de l'insuffisance renale chronique. Thérapie 35: 365–367
Knothe H, Dette GA (1977) Pharmacokinetics of erythromycin. Scot Med J 22: 397–400
Prandota J, Tillement JP, D'Athis P, Campos H, Barre J (1980) Binding of erythromycin base to human plasma proteins. J Int Med Res 8: (Suppl 2): 1–8
Reidenberg MM, Kostenbauder H, Adams WP (1969) Route of drug metabolism in obese volunteers before and during starvation and in azometic patients. Metabolism 18: 209–213
Ritschel WA (1981) Handbook of basic pharmacokinetics. Hamilton Press, Hamilton, II, USA, p 417
Rutland J, Berend N, Marlin GE (1979) The influence of food on the bioavailability of new formulations of erythromycin stearate and base. Br J Clin Pharmacol 8: 343–347
Sande MA, Mandell GL (1980) Antimicrobial agents. In: Goodman L, Gilman A (eds), The pharmacological basis of therapeutics. Macmillan, New York, pp 1222–1248
Simpson JS, Kavanagh F (1963) Microbiological assay using large plate methods. Analytical microbiology, Vol. 1. Academic Press, New York, pp 87–124
Sutherland R, Rolinson GN (1978) In: Reeves DS, Phillips I, Williams JD, Wise R (eds) Methods of antibiotic assay-penicillins. Laboratory methods in antimicrobial chemotherapy. Churchill Livingstone, Edinburgh, pp 171–178
Vaziri ND, Cessario TC, Valentic J, Saiki JK, Tilles JG (1980) Haemodialysis of erythromycin. Drug Intell Clin Pharmacol 14: 549–551
Welling PG, Craig WA (1978) Pharmacokinetics of intravenous erythromycin. J Pharm Sci 67: 1057–1059
Welling PG, Elliott RL, Pitterle ME, Corrick-West HP, Lyons LL (1979) Plasma levels following single and repeated doses of erythromycin estolate and erythromycin stearate. J Pharm Sci 68: 150–155
Wiegand RG, Chun AHC (1972) Serum protein binding of erythromycin and erythromycin 2-proprionate ester. J Pharm Sci 61: 425–428
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Iliopoulou, A., Downey, K., Chaput de Saintonge, D.M. et al. Should erythromycin dose be altered in haemodialysis patients?. Eur J Clin Pharmacol 23, 435–440 (1982). https://doi.org/10.1007/BF00605994
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00605994